aTyr PharmaATYR
Market Cap: $142M
About: aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Employees: 59
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
75% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 12
69.69% more ownership
Funds ownership: 0% [Q1] → 69.69% (+69.69%) [Q2]
8% less capital invested
Capital invested by funds: $81.6M [Q1] → $75M (-$6.53M) [Q2]
20% less funds holding
Funds holding: 56 [Q1] → 45 (-11) [Q2]
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $8K
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Jefferies Roger Song 43% 1-year accuracy 3 / 7 met price target | 379%upside $9 | Buy Initiated | 5 Sept 2024 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 1,762%upside $35 | Buy Reiterated | 15 Aug 2024 |
RBC Capital Gregory Renza 45% 1-year accuracy 32 / 71 met price target | 751%upside $16 | Outperform Reiterated | 14 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 1,762%upside $35 | Buy Reiterated | 1 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 1,762%upside $35 | Buy Reiterated | 22 Jul 2024 |